ReviewMolecular diagnosis & therapy2021
Hepatic Clearance of Cell-Free DNA: Possible Impact on Early Metastasis Diagnosis.
Review in Molecular diagnosis & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Feasibility of serial cfDNA measurement after perflubutane microbubble (SonazoidBMC research notes · 2026Article
- Circulating cell-free mitochondrial DNA in diabetes mellitus: Current insights and unexplored frontiers.Journal of diabetes investigation · 2025Review
- Donor-derived cell-free DNA-based liquid biopsies to determine future kidney transplant rejection.Kidney research and clinical practice · 2025Article
- Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Observational
- Modulating cell-free DNA biology as the next frontier in liquid biopsies.Trends in cell biology · 2025Review
- Prenatal Cell-Free DNA Sequencing and Intrahepatic Cholangiocarcinoma.JCO precision oncology · 2025Article
- Recent advances in ctDNA detection using electrochemical biosensor for cancer.Discover oncology · 2024Review
- Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies.Science (New York, N.Y.) · 2024Article
- Bladder cancer.Nature reviews. Disease primers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating DNA in the bloodstream has been studied since the 1940s, leading to its identification as a possible early marker for the presence of a primary tumor. Recently, it has been more successfully employed in liquid biopsies to determine the early presence of a metastatic tumor arising after chemotherapy, radiotherapy, and surgery. The appearance of such circulating tumor DNA permits the identification of the metastatic tumor before it is detected by either palpation or radiological analysis. Nevertheless, the liquid biopsy may possibly be affected by the removal of circulating tumor DNA via the kidneys and spleen as it is released. Furthermore, the liver removal of cell-free DNA has not yet been considered to be involved in this process. Here, we review the literature on the removal of free single- and double-stranded DNA and nucleosomal, vesicular, and exosomal DNA via the liver and examine its possible impact on circulating DNA levels. The removal of all forms of DNA by the liver, together with that removed by the kidneys and spleen, may delay the timing of positive results from liquid biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.